坎地沙坦对老年充血性心力衰竭患者利钾尿肽、心房钠尿肽和内皮素水平的影响

目的: 探讨血管紧张素II受体拮抗剂（ARB）坎地沙坦治疗充血性心力衰竭（CHF）时对外周血中利钾尿肽（KP）、心房钠尿肽（ANP）和内皮素（ET）水平的影响。方法: 94例老年CHF患者随机分为常规治疗组（硝酸酯类药物+利尿剂+地高辛）和坎地沙坦组（常规治疗药物+坎地沙坦）,随访12 周,采用放射免疫分析方法测定两组治疗前后和34例健康者（正常对照组）外周血浆中KP、ANP和ET水平。同时用核素心室显像测定CHF患者左心室射血分数（LVEF）。结果: CHF患者的血浆KP、ANP和ET水平较正常对照组显著升高,随着病情的好转其水平逐渐降低,且不同的心功能分级之间有显著差异（P<0.05）。治疗后,坎地沙坦组外周血中KP、ANP和ET水平较常规治疗组下降更显著。结论: 坎地沙坦有抑制CHF患者神经内分泌的过度激活和肾素-血管紧张素-醛固酮(RAAS)系统亢进的作用。     

利钾尿肽、心房钠尿肽在充血性心力衰竭患者中的变化

目的:研究利钾尿肽（KP）在和心房钠尿肽（ANP）充血性心力衰竭（CHF）中的变化及其意义。方法:用放射免疫分析方法测定50例患者发病不同时期血浆KP和ANP含量。结果:CHF患者在发病第1天血浆KP、ANP水平最高,随着病情的好转而逐渐降低,不同的心功能分级之间有显著差异,KP水平与左室射血分数呈显著负相关。结论:血浆KP水平在CHF病理生理中的改变有重要意义。     

强心胶囊治疗老年慢性心力衰竭48例

目的探讨强心胶囊治疗老年慢性充血性心力衰竭(CHF)的疗效。方法入选48例门诊及住院确诊的老年慢性充血性心力衰竭患者,随机分为两组。两组常规运用利尿剂、血管紧张素转换酶抑制剂等西药治疗。治疗组加用强心胶囊;对照组加用地高辛片,连用1个月为1个疗程。治疗前后分别进行左室射血分数(LVEF)、6min步行距离的评估,并比较两组临床疗效。结果治疗前两组、LVEF和6min步行距离无统计学意义(P>0.05);治疗后两组心功能均较治疗前明显改善,差异有统计学意义(P<0.01),与对照组治疗后比较,治疗组LVEF、6min步行距离升高明显(P<0.05)。结论强心胶囊能明显提高老年CHF患者的LVEF及6min步行距离,提高心功能,改善患者生活质量。     

益心舒胶囊治疗气阴两虚挟瘀型慢性充血性心力衰竭的疗效观察

目的 观察益心舒胶囊治疗气阴两虚挟瘀型慢性心力衰竭(CHF)的临床疗效.方法 将100例CHF患者随机分为治疗组(50例)与对照组(50例).对照组予常规西药治疗,治疗组在西药常规治疗基础上加用益心舒胶囊.结果 两组均能够改善CHF患者中医证候积分,心功能等级,左室射血分数(LVEF),但改善程度治疗组优于对照组(P<0.05).结论 益心舒胶囊治疗慢性心力衰竭疗效确切.     

探讨非洛地平治疗慢性充血性心力衰竭（CHF）的临床疗效和药学特点

目的研究非洛地平治疗慢性充血性心力衰竭(CHF)的临床疗效和药学特点。方法本次纳入2018年5月至2019年4月收治的72例慢性充血性心力衰竭患者展开研究,按照随机数字表法分为两组,对照组36例进行常规治疗,观察组36例加用非洛地平治疗。将两组的血压水平、心率、心功能指标、临床效果进行比对。结果观察组患者治疗后的血压、心率、左室舒张末期内径、左室收缩末期内径均低于对照组,左室射血分数及临床总有效率高于对照组(P0.05)。结论在CHF患者的治疗中加用非洛地平的药学效果显著。     

益心舒胶囊治疗慢性心力衰竭的临床研究

目的 研究益心舒胶囊治疗慢性充血性心力衰竭(CHF)的疗效.方法 98例CHF患者随机分为治疗组和对照组,每组49例.对照组以常规抗心力衰竭西药治疗,治疗组在对照组治疗基础上加用益心舒胶囊(每次3粒,每日3次,口服).两组疗程均为3个月.观察治疗前后NYHA心功能分级、左室射血分数(LVEF)和6 min步行试验(6MWT)等.结果 治疗组治疗总有效率达93.9%,对照组治疗总有效率为79.6%(P<0.05).结论 益心舒胶囊是治疗CHF的有效药物.     

益心舒胶囊治疗慢性充血性心力衰竭的临床研究

目的 评价益心舒胶囊治疗慢性充血性心力衰竭(CHF) 的临床疗效和安全性.方法 将146 例CHF 患者随机分为益心舒胶囊组(A组,110例)和对照组(B组,36例),两组均应用洋地黄、利尿剂、血管紧张素转换酶抑制剂(ACEI) 和血管紧张素Ⅱ(Ang Ⅱ)受体阻滞剂(ARB)、β受体阻滞剂等基础治疗.A组同时加服益心舒胶囊1.2 g,每日3次.治疗前及治疗10 周后测定两组相关指标,并进行比较.结果 两组治疗后心功能均明显改善,心功能改善有效率比较有统计学意义(P<0.05);两组治疗后超声心动图左室射血分数(LVEF)及心排指数(CI)比较均有统计学意义(P<0.01).两组安全指标比较无统计学意义.结论 益心舒胶囊治疗慢性充血性心力衰竭有效且安全.     

益心舒胶囊对慢性充血性心力衰竭患者心功能及血浆脑钠肽的影响

目的观察益心舒胶囊对慢性充血性心力衰竭（CHF）患者心功能及血浆脑钠肽（BNP）的影响。方法入选慢性充血性心力衰竭患者80例,随机分为两组,对照组给予常规的抗心力衰竭治疗,治疗组在对照组基础上加用益心舒胶囊。3个月为1个疗程。分别于治疗前后观察两组6min步行试验（6MWT）、超声心动图、血浆BNP水平变化。结果治疗组总有效率为82．5％,高于对照组的60．0％（P〈0．05）。治疗组治疗后心功能较治疗前明显改善（P〈0．05）,BNP水平均较治疗前明显下降（P〈0．05）;与对照组治疗后比较,治疗组心功能改善更明显（P〈0．05）,血浆BNP下降幅度更大（P〈0．05）。结论益心舒胶囊联合常规抗心力衰竭药物治疗能有效改善CHF患者心功能,降低血浆BNP水平。     

芪苈强心胶囊治疗慢性充血性心力衰竭40例

目的探讨芪苈强心胶囊治疗慢性充血性心力衰竭（CHF）的临床疗效。方法将80例CHF病人随机分为两组,两组均应用洋地黄、利尿剂、血管紧张素转换酶抑制剂等常规治疗心力衰竭药物,治疗组加服芪苈强心胶囊。结果治疗8周后两组治疗后左室射血分数、心排血量、左室搏出量均较治疗前增加（P〈0.05）;两组治疗后左房内经（LA）、左室舒张末内径（Dd）、左室收缩末期内径（Ds）均较治疗前明显缩小（P〈0.05或P〈0.01）,且治疗组明显优于对照组（P〈0.05）。结论芪苈强心胶囊治疗CHF可有效改善心功能。     

益心舒胶囊治疗充血性心力衰竭100例疗效观察

目的观察益心舒胶囊治疗充血性心力衰竭(CHF)的临床疗效。方法将200例CHF病人随机分为两组,对照组采用常规抗心力衰竭药物治疗,治疗组在对照组治疗基础上加入益心舒胶囊1.2g,每日3次。疗程为8周。结果治疗组临床症状、心电图改善总有效率分别为85%、84%,对照组分别为74%、72%,两组比较差异有统计学意义(P0.05)。结论益心舒胶囊治疗充血心力衰竭有效且安全性较高。并对提高病人生活质量,提高生存率有一定疗效。     

Peptide Receptor Imaging

Radiolabeled cell-surface peptide receptor-binding molecules are emerging as an important class of radiopharmaceuticals. Their binding to specific cell membrane receptors allows for noninvasive assessment of regional receptor proteomics in vivo. Information thus obtained can be used for diagnostic purposes and for predicting and monitoring response to treatment. This paradigm also applies to pulmonary diseases. In this review, available radiopharmaceuticals of great potential or already in clinical use for imaging of lung cancer, lung inflammation and infection and pulmonary embolism are discussed.In lung cancer, somatostatin receptor imaging by means of technetium-99m (^99mTc)-octreotide scintigraphy has proven useful for characterizing malignancy in solitary pulmonary nodules. Additionally, several radiopharmaceuticals targeting tyrosine-kinase, e.g. ^99mTc labeled epidermal growth factor and indium-111 (¹¹¹In)-diethylene triamine penta-acetic acid-trastuzumab, or G-protein coupled receptors, e.g. ^99mTc-bombesin, iodine-123-vasoactive intestinal peptide and ¹¹¹In-tetraazacyclododecane tetra-acetic acid (DOTA)-cholecystokinine-B, are being explored for their diagnostic as well as treatment monitoring potential.With the purpose of better evaluating the source of pulmonary embolism, as well as to differentiate acute from chronic deep venous thrombosis, several radiolabeled peptides targeting the glycoprotein IIb/IIIa fibrinogen receptor found on activated platelets have been developed. Out of these, ^99mTc-P280 is now approved by the US Food and Drug Administration for scintigraphic imaging of suspected acute venous thrombosis in the lower extremities of patients.In the field of lung inflammation and infection, non-specific ¹¹¹In and ^99mTc-human polyclonal immunoglobulins have been successfully used to identify the presence and extent of Pneumocystis carinii, cytomegalovirus, Mycobaterium avium and fungal infections in patients with HIV infection. The clinical role of other radiopharmaceuticals such as ^99mTc-J001X, a nonpyrogenic acylated polygalactoside isolated from Klebsiella pneumoniae and binding with high affinity to CD11b and CD14 lipopolysaccharide receptors expressed on monocytes/macrophages, and ¹¹¹In-octreotide, binding to up-regulated somatostatin receptors on activated lymphocytes needs to be further defined.     

Glucagon-like Peptide 2

Glucagon-like peptide 2 (GLP-2) is secreted in a nutrient-dependent manner from enteroendocrine cells throughout the gastrointestinal tract and is trophic to the intestinal epithelial mucosa. GLP-2 acts via stimulation of crypt cell proliferation and inhibition of cell death. GLP-2 also stimulates intestinal glucose transport, decreases mucosal permeability, and shows therapeutic efficacy in experimental models of short bowel syndrome and both small and large bowel inflammation.     

Peptide antisense nanoparticles

We have designed a heterofunctionalized nanoparticle conjugate consisting of a 13-nm gold nanoparticle (Au NP) containing both antisense oligonucleotides and synthetic peptides. The synthesis of this conjugate is accomplished by mixing thiolated oligonucleotides and cysteine-terminated peptides with gold nanoparticles in the presence of salt, which screens interactions between biomolecules, yielding a densely functionalized nanomaterial. By controlling the stoichiometry of the components in solution, we can control the surface loading of each biomolecule. The conjugates are prepared easily and show perinuclear localization and an enhanced gene regulation activity when tested in a cellular model. This heterofunctionalized structure represents a new strategy for preparing nanomaterials with potential therapeutic applications.     

Peptide Inhibitors of Renin

Three experiments are described using new substrate analogue inhibitors of renin. The first experiment shows that introduction of a reduced isostere in the scissile peptide bond of an analogue greatly increases its ability to inhibit renin of a particular species. However, different species of renin substrate have different amino acids in their scissile bond and variation here also greatly influences the affinity of renin and substrate and hence of renin and substrate analogues. Finally, substitution of amino acids in the C-terminal adjacent to the scissile bond influences the affinity and efficacy of substrate analogues as inhibitors. In our second experiment a peptide inhibitor of dog renin, H.77, was used in an affinity column to produce a one-stage, 2000-fold, and complete purification of human renin. In our third experiment infusion of H.77 was used to lower circulating concentrations of angiotensin I and angiotensin II in conscious sodium-deplete dogs. Captopril was then given in addition to H.77 but blood pressure did not fall further, suggesting that captopril lowers blood pressure wholly or partly by reducing angiotensin II within the circulation and in extravascular sites.     

脑血管病患者血浆降钙素基因相关肽的测定及临床意义

采用放免法测定了１０８例脑血管病（ＣＶＤ）患者的乐降钙素基因相关肽（ＣＧＲＰ）水平。结果６２例脑梗塞（ＣＩ）患者（ＣＩ组）显著低于对照组，发病２４小时内即显著降低，２－７天进一步降低；８－１５天开始升高，１５天后逐渐升至正常水平，４６例脑出血（ＣＨ）患者（ＣＨ组）亦显著     

罗格列酮与利钠肽

罗格列酮是临床常用的糖尿病治疗药物,临床及实验室研究发现,它在心血管系统也发挥很多作用,它可以抑制心肌肥厚、改善心脏重构、减少缺血再灌注后的损伤、改善血管内皮功能等等,但同时它也会引起水钠潴留等不良反应从而引起心力衰竭。利钠肽是一类内分泌激素,在心血管系统中同样发挥重要的作用,它可以减轻心脏的前、后负荷,从而改善心力衰竭等症状。现就罗格列酮与利钠肽两者在心血管系统的作用以及罗格列酮对利钠肽的影响作用做一综述。